STOCK TITAN

[Form 4] VolitionRX Limited Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

VolitionRX Limited director Ethel Rubin was awarded 17,424 restricted stock units (RSUs) on August 15, 2025 under the companys 2015 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in six approximately equal monthly installments beginning August 1, 2025, and once earned they remain subject to further time-based vesting in two equal installments of 8,712 units on each of November 1, 2025 and February 1, 2026. Vesting and settlement will deliver common stock equal to the number of RSUs earned and vested, and continued service is generally required through each applicable earning and vesting date. Following the award, the reporting person beneficially owns 62,948 shares. The Form 4 was signed by Ethel Rubin on August 19, 2025.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Director compensation awarded as RSUs aligns pay with shareholder outcomes and ties retention to service-based vesting.

The award of 17,424 RSUs in lieu of cash is a common governance practice to align a directors interests with shareholders and to conserve cash. The structuresix monthly earning installments followed by two time-based vesting datescreates both near-term earning and multi-month retention incentives. This is routine for board compensation and does not on its face indicate governance concerns; materiality is limited given the size of the award relative to the companys outstanding shares (not disclosed here).

TL;DR: RSUs convert to common stock upon vesting, causing potential dilution when settled; timing is defined but dollar impact is unspecified.

The filing clearly states the RSUs will settle into common shares equal to vested units, which will increase outstanding share count upon settlement. The award replaces cash compensation, so immediate cash outflow is avoided. Because the filing does not disclose the total share base or percentage dilution, the economic impact cannot be quantified from this form alone.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rubin Ethel

(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD,
SUITE 110

(Street)
HENDERSON NV 89014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 A 17,424(1) A $0 62,948 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On August 15, 2025, the reporting person was awarded 17,424 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs are earned in six approximately equal monthly installments commencing on August 1, 2025. Once earned, they will remain subject to additional time-based vesting in two equal installments of 8,712 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date.
Remarks:
/s/ Ethel Rubin 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

30.84M
101.74M
17.84%
22.29%
0.28%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON